What is Happening to the Food Supply Chain?

 

Every industry’s supply chain has been impacted by the COVID-19 pandemic, forcing key players to be agile and flexible in response.

But what about for the industry that quite literally fuels us all?

On this episode of MarketScale Live, host and Voice of B2B Daniel Litwin was joined by Kevin C. Kenny, Chief Operating Officer for Decernis, a FoodChain ID company, to discuss how the food supply chain, particularly as it relates to meat, has been affected.

Kenny’s primary focus is on the safety of the food supply chain and of the food itself and regulations surrounding the way products move through the food supply chain. In fact, he said Decernis has over 100,000 regulations that it tracks to help identify what’s happening at every step of the supply chain process.

Now, in light of the COVID-19 pandemic, the pace has picked up significantly.
“There’s been an incredible amount fluidity,” Kenny said. “Every day I wake up, and there’s a new situation. There are new problems to talk about, and there are new challenges in the supply chain. … I’ve been doing this for 25 years, and I’ve never been through anything quite as exciting.”

Key bottlenecks and focal points related to the COVID-19 disruption exist in working to ensure worker safety during the pandemic, particularly in the meat industry, attempting to mitigate more potential disruptions in getting goods from place to place, and more.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More